In this presentation, the bioanalytical challenges in developing novel drug delivery systems will be discussed and solutions will be explored to overcome these challenges. The focus will be on nanomedicines and anti-body drug conjugates. Ardena is a fully integrated contract development and manufacturing organization (CDMO) as well as a fully integrated contract research organization (CRO). Ardena is globally recognized as a leader in the development and manufacture of advanced drug delivery systems based on nanoparticles.

At Ardena Bioanalysis in Assen we offer a full range of bioanalytical services, catering to both non-regulated early drug discovery and regulated pre-clinical and clinical phases. Our expertise extends across various types of drug products and biomarkers, including small molecules, proteins (including antibodies, antibody-drug conjugates, and oligonucleotides), and more.

Two case studies will be discussed. The first study concerns the determination of an antibody drug conjugate (ADC) in human plasma using an ultra-high performance liquid chromatography system hyphenated with a tandem mass-spectrometer (LC-MS/MS) instead of a conventional Enzyme-Linked Immuno-Sorbent Assay (ELISA) and the second study concerns the analysis of a polypeptide-functionalized superparamagnetic iron oxide nanoparticle in plasma and tissue.

More information can be found on the website of the lecture.